Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Nitrosamine impurities (NDMA/NDEA)

Trace nitrosamine impurities such as NDMA, NDEA or NMBA found above the acceptable daily limit. Nitrosamines are probable human carcinogens that can form during manufacturing or storage. This is the cause behind the large valsartan, losartan and ranitidine (Zantac) recalls.

568 FDA drug recalls with this cause, newest first.

Nitrosamine compounds such as NDMA, NDEA or NMBA are probable human carcinogens that can form during manufacturing or storage. Recalls here trace back to a nitrosamine found above the accepted limit - whether the report names the compound or simply calls it a 'carcinogenic impurity'. It is a newer category, driven by improved testing methods that can now detect impurities that were previously missed, and it is the chemistry behind the large valsartan, losartan and ranitidine (Zantac) recalls.

Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Ongoing Nitrosamine impurity Granules India Limited NDC 62207-773-32 D-0632-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Presence of NDMA impurity detected in product.

Terminated Nitrosamine impurity Preferred Pharmaceuticals, Inc NDC 68788-7078-03 D-0617-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Ongoing Nitrosamine impurity Amneal Pharmaceuticals, Inc. NDC 53746-254-02 D-0616-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Ongoing Nitrosamine impurity Amneal Pharmaceuticals, Inc. NDC 53746-253-10 D-0615-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Ongoing Nitrosamine impurity Amneal Pharmaceuticals, Inc. NDC 65162-254-30 D-0613-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Impurity N-nitrosodimethylamine (NDMA) found in API

Ongoing Nitrosamine impurity Amneal Pharmaceuticals, Inc. NDC 65162-253-06 D-0612-2020
Class II · Moderate risk

Ranitidine Tablets

CGMP Deviations: Potential N-Nitrosodimethylamine (NDMA) amounts above levels established by the FDA.

Terminated Nitrosamine impurity American Health Packaging D-1003-2020
Class II · Moderate risk

Ranitidine Syrup

CGMP Deviations: N-nitrosodimethylamine (NDMA) has been detected in Ranitidine tablets, capsules and syrups.

Ongoing Nitrosamine impurity AuroMedics Pharma LLC NDC 65862-431-74 D-0529-2020
Class II · Moderate risk

Ranitidine Syrup

CGMP Deviations: Presence of NDMA impurity detected in product.

Terminated Nitrosamine impurity American Health Packaging NDC 60687-260-69 D-0631-2020